Evidence map›Paper›PMID 40996485›Full record

Trial reportThe European journal of health economics : HEPAC : health economics in prevention and care2026

Cost-utility analysis of a web-based interactive patient education platform: evidence from a randomized clinical trial for end-stage renal disease patients.

Modou Diop, Lionel Perrier, Baptiste Haon, Lise Rochaix, Luc Behaghel, Jean-Claude K Dupont, Magali Morelle, Michelle Elias, Laure Esposito, Christophe Legendre and 4 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Modou DiopHospinnomics (Paris School of Economics & Assistance Publique - Hôpitaux de Paris), Hôtel Dieu 1 Parvis Notre-Dame, Paris, 75004, France. modou.diop@psemail.eu.ORCID http://orcid.org/0000-0003-0934-4005
Lionel PerrierCentre Léon Bérard, CNRS, Université Lumière Lyon 2, Université Jean Monnet Saint-Etienne, Emlyon Business School, GATE, Lyon, 69008, France.
Baptiste HaonHospinnomics (Paris School of Economics & Assistance Publique - Hôpitaux de Paris), Hôtel Dieu 1 Parvis Notre-Dame, Paris, 75004, France.
Lise RochaixHospinnomics (Paris School of Economics & Assistance Publique - Hôpitaux de Paris), Hôtel Dieu 1 Parvis Notre-Dame, Paris, 75004, France.
Luc BehaghelParis School of Economics, Paris, France.
Jean-Claude K DupontInstitut Pasteur, Ethics Unit, Paris, France.
Magali MorelleUniv Lyon, Leon Berard Cancer Center, GATE UMR 5824, 28 Prom. Léa et Napoléon Bullukian, Lyon, F-69008, France.
Michelle EliasNephrology and Dialysis Department, Bicêtre Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Laure EspositoNephrology and Dialysis Department, CHU Toulouse - Hôpital de Rangueil, Toulouse, France.
Christophe LegendreNephrology and Dialysis Department, Necker-Enfants Malades Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Hélène LonguetNephrology and Dialysis Department, CHRU Tours - Hôpital Bretonneau, Tours, France.
Isabelle Durand-ZaleskiUniversity of Paris Cité, Paris, France.
Evangéline PilleboutNephrology and Dialysis Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
PIC-R trial Investigators

Funding

Assistance Publique - Hôpitaux de Paris IC150643
6 · The paper itself

Abstract

objectivesChronic kidney disease and its most severe complication, end-stage renal disease (ESRD), represents an estimated financial burden of €4.4 billion in 2021 in France. Therapeutic patient education (TPE) improves ESRD management and health outcomes. This study explored whether providing access to an interactive web-based TPE platform with community features was cost-effective.

methodsA within-trial cost-utility analysis was carried out over an 18 months horizon, using data from the PIC-R (Plateforme Interactive Communautaire-dialyse et transplantation Rénale) trial. ESRD or post-transplant patients were randomized 1:1:1 to a control group with no specific TPE program (Control), an intervention group with online TPE (e-TPE) and an intervention group with online TPE coupled with community features such as a patient forum and a chatroom with both patients and health care professionals (e-TPE + chat). The outcome measure was the cost per quality-adjusted life-year (QALY) and per year of full capability (YFC). Both intention-to-treat (ITT) and per protocol (PP) analyses were conducted, and missing data were handled using multiple imputation and selection models. Sensitivity analyses were performed.

resultsAmong the 815 patients assessed for eligibility across 12 French centres, a total of 549 patients were included in the economic analysis: 186 in the Control group, 189 in the e-TPE group and 174 in the e-TPE + chat group. The e-TPE group demonstrated cost savings and slightly higher QALYs compared to the control group, making e-TPE dominant. Conversely, the e-TPE + chat intervention resulted in higher costs without substantial effectiveness gains, making it not cost-effective.

conclusionse-TPE was deemed cost-effective for ESRD patients, while e-TPE + chat was not. Web-based platforms improve ESRD management when targeted to likely users.

Indexed as

InternetKidney Failure, ChronicPatient Education as TopicAdultAgedCost-Benefit AnalysisFemaleFranceHumansMaleMiddle AgedQuality-Adjusted Life YearsCost-effectiveness analysisCost-utility analysisEnd-stage renal diseasePatient therapeutic educationRandomized clinical trialWeb-based intervention.

Identifiers

PMID40996485
PMCPMC13190348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.